Patents

The present invention relates to a method of analyzing a biofluid of a subject for the presence of bacterial extracellular vesicles (EV), said method comprising the steps of a) extracting bacterial EV from said biofluid, b) analyzing said bacterial EV-extracted molecular patterns for the presence of a disease marker, wherein said disease marker is a disease-specific molecular pattern of said subject; and said subject comprising patients diagnosed with HIV, IBD or cancer or said subject receiving a treatment.

The present invention provides a method and electrochemical system for the electrochemical detection of microbial metabolic activity, in particular living microorganism, in a sample or the detection of an antimicrobial compound in a sample using a redox mediator and an electrode system, wherein the metabolic activity or growth of a microorganism (present in or added to the sample) is assessed by measuring an electrical signal, in particular a potential or current output, via the electrode system, which is a measure of the oxidation of a redox mediator (in reduced form) at an electrode. The ...

The present invention is directed to selective detection of monomeric C-reactive protein (CRP) in a body fluid sample. In particular, the present invention provides the use of a DNA aptamer for the detection of monomeric CRP in an isolated sample of body fluid from a subject. The invention also provides DNA aptamers that specifically bind to monomeric CRP. Finally, also a detection method for monomeric CRP in a body fluid sample using a DNA aptamer and a kit for the detection of monomeric CRP in a body fluid sample are described.

The present invention to the identification of a novel isolated bacterial strain, the Limosilactobacillus reuteri strain which is characterized by a naturally occurring overproduction of riboflavin (vitamin B2) compared to other known strains of lactobacilli. Said strain of the Limosilactobacillus species is deposited under accession number LMG P-32020. In a further aspect, also the uses of said L. reuteri strain are disclosed herein. In particular, the use of said strain in food and feed industry, human and veterinary health, large-scale vitamin production, cosmetics and consumer care ...

The present invention in general relates to the field of DNA methylation detection. More in particular the current invention provides a method for DNA methylation detection using a combination of methylation-specific restriction enzymes (MSRE) and single molecule Molecular Inversion Probes (smMIPs). The present invention also provides uses of said DNA methylation detection method such as but not limited to the field of cancer diagnosis and/or monitoring

The present invention provides methods and kits for preparing a collection of degraded DNA fragments isolated from a biofluid sample of an individual. The prepared collection of nucleic acid sequences can be used in a diagnostic method such as for example detection and/or prognosis of cancer.

The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.

The present invention applies to the area of cancer diagnostics. In particular, the present invention is directed to a method for the ex vivo differential diagnosis between several cancer types in a subject based on the methylation status of the Gasdermin E (GSDME) gene. In a further aspect, the present invention relates to a method for the ex vivo differential diagnosis between several cancer types based on the methylation status of at least 2 CpG sites in the GSDME gene.

The invention relates to a device and a method for growing and screening of plant samples, comprising a specialized multiwell plate system well-suited for housing granular media, for use in in vivo screening methods of uninterrupted plant tissue growth.

Provided herein relate to modified or mutant forms of cytolysin A (ClyA) and compositions comprising the same. In particular, the modified or mutant forms of ClyA permits efficient capture and/or translocation of a target negative-charged molecule or polymer through the modified or mutant ClyA nanopores at low or physiological ionic strengths. Thus, methods for using the modified or mutant forms of ClyA and compositions, for example, for characterizing a target negatively-charged analyte, e.g., a target polynucleotide, are also provided.